Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile.
美國德克薩斯州奧斯汀，2024年9月5日（全球新聞社）- lumos pharma公司（NASDAQ:LUMO）是一家臨床階段罕見病治療藥物公司，專注於罕見病治療。今天宣佈，其第2期OraGrowtH210和OraGrowtH212臨床試驗數據的更新分析已被接受，並將在2024年9月11日至14日的智利聖地亞哥舉行的《拉丁美洲兒童內分泌學會學術研討會》（Sociedad Latinoamericana de Endocrinología Pediátrica，簡稱SLEP 2024）上進行展示。
Abstract Presentation: Friday, September 13th – E-poster Session 2 – 1:15-2:30PM Local Time
摘要展示：9月13日星期五-電子海報展示2-本地時間下午1:15-2:30
- Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials (Rossana Román, MD, et al)
- 摘要標題：LUm-201恢復了中度兒童生長激素缺乏（PGHD）的生長激素分泌和促進生長：來自OraGrowtH210和OraGrowtH212試驗的第2期排名結果（Rossana Román醫生等）
About Lumos Pharma
關於Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit .
路莫斯製藥公司是一家臨床階段的生物製藥公司，專注於罕見病治療藥物的研發和商業化。公司由一支在罕見病藥物研發方面擁有長期經驗的管理團隊創立和領導。路莫斯製藥的主要治療候選藥物LUm-201是一種新型的口服生長激素（GH）分泌劑，旨在將全球價值約47億美元的GH市場從注射劑轉化爲口服治療。LUm-201目前正在多項2期臨床研究中評估用於兒童生長激素缺乏症（PGHD）並已在美國和歐盟均獲得了孤兒藥物認證。有關更多信息，請訪問該公司的網站。
Investor & Media Contact:
投資者及媒體聯繫方式： Lisa Miller Lumos Pharma投資者 Relations 512-792-5454 ir@lumos-pharma.com 來源：Lumos Pharma, Inc。
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Lisa Miller
Lumos Pharma投資者 Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
來源：Lumos Pharma, Inc。
譯文內容由第三人軟體翻譯。